$UBX
Unity Biotechnology, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023039784 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.430M $5.433M
YoY Change -10.0% 9.96%
% of Gross Profit
Research & Development $4.901M $6.529M
YoY Change -40.29% -13.56%
% of Gross Profit
Depreciation & Amortization $310.0K $314.0K
YoY Change -42.06% -48.44%
% of Gross Profit
Operating Expenses $14.93M $11.96M
YoY Change 13.72% -4.26%
Operating Profit -$14.93M -$11.96M
YoY Change 13.72% -2.41%
Interest Expense $470.0K $979.0K
YoY Change -45.73% 9.51%
% of Operating Profit
Other Income/Expense, Net -$577.0K -$69.00K
YoY Change 1307.32% 60.47%
Pretax Income -$15.29M -$12.21M
YoY Change 11.54% -7.09%
Income Tax
% Of Pretax Income
Net Earnings -$15.29M -$12.21M
YoY Change 11.53% -7.09%
Net Earnings / Revenue
Basic Earnings Per Share -$1.05 -$0.85
Diluted Earnings Per Share -$1.05 -$0.85
COMMON SHARES
Basic Shares Outstanding 14.60M 14.37M
Diluted Shares Outstanding 14.60M 14.43M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.90M $69.09M
YoY Change -53.61% 7.11%
Cash & Equivalents $7.876M $19.12M
Short-Term Investments $38.10M $49.97M
Other Short-Term Assets $3.600M $3.874M
YoY Change -4.86% 16.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $49.54M $72.97M
YoY Change -51.78% 7.58%
LONG-TERM ASSETS
Property, Plant & Equipment $5.314M $25.24M
YoY Change -35.21% 190.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.899M
YoY Change
Other Assets $0.00 $901.0K
YoY Change -100.0% 1353.23%
Total Long-Term Assets $19.73M $28.04M
YoY Change -41.39% -5.81%
TOTAL ASSETS
Total Short-Term Assets $49.54M $72.97M
Total Long-Term Assets $19.73M $28.04M
Total Assets $69.27M $101.0M
YoY Change -49.21% 3.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.149M $1.449M
YoY Change -52.99% 0.84%
Accrued Expenses $5.258M $7.069M
YoY Change 14.48% 53.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $13.70M
YoY Change -100.0% 93.37%
Total Short-Term Liabilities $8.633M $22.22M
YoY Change -48.53% 35.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $4.082M
YoY Change -100.0% -67.78%
Other Long-Term Liabilities $24.40M $25.30M
YoY Change
Total Long-Term Liabilities $0.00 $29.38M
YoY Change -100.0% 131.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.633M $22.22M
Total Long-Term Liabilities $0.00 $29.38M
Total Liabilities $33.06M $51.60M
YoY Change -42.82% -10.51%
SHAREHOLDERS EQUITY
Retained Earnings -$498.3M -$483.0M
YoY Change 11.78% 11.78%
Common Stock $534.6M $532.6M
YoY Change 1.9% 12.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.21M $49.41M
YoY Change
Total Liabilities & Shareholders Equity $69.27M $101.0M
YoY Change -49.21% 3.5%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$15.29M -$12.21M
YoY Change 11.53% -7.09%
Depreciation, Depletion And Amortization $310.0K $314.0K
YoY Change -42.06% -48.44%
Cash From Operating Activities -$7.110M -$11.08M
YoY Change -34.51% -25.29%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $0.00
YoY Change -120.83% -100.0%
Acquisitions
YoY Change
Other Investing Activities $14.26M $9.854M
YoY Change -139.41% -44.34%
Cash From Investing Activities $14.25M $9.854M
YoY Change -139.33% -44.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -18.38M -2.625M
YoY Change -136.6% -2002.17%
NET CHANGE
Cash From Operating Activities -7.110M -11.08M
Cash From Investing Activities 14.25M 9.854M
Cash From Financing Activities -18.38M -2.625M
Net Change In Cash -11.24M -3.854M
YoY Change -458.65% -228.64%
FREE CASH FLOW
Cash From Operating Activities -$7.110M -$11.08M
Capital Expenditures $10.00K $0.00
Free Cash Flow -$7.120M -$11.08M
YoY Change -34.12% -25.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001463361
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38470
dei Entity Registrant Name
EntityRegistrantName
Unity Biotechnology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4726035
dei Entity Address Address Line1
EntityAddressAddressLine1
285 East Grand Ave.
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
416-1192
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
dei Trading Symbol
TradingSymbol
UBX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14601258
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19118000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12736000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
49974000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82059000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3874000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1740000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
72966000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96535000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7181000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7825000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18061000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19042000
CY2023Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1899000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
896000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
52000
CY2023Q2 us-gaap Assets
Assets
101008000
CY2022Q4 us-gaap Assets
Assets
124350000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1449000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1790000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1652000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3020000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5417000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5334000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
13704000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9476000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22222000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19620000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25297000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26991000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4082000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10891000
CY2023Q2 us-gaap Liabilities
Liabilities
51601000
CY2022Q4 us-gaap Liabilities
Liabilities
57502000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14595477
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14595477
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14215302
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14215302
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
532563000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
527049000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-136000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-251000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-483021000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-459951000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
49407000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66848000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101008000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124350000
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6529000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7553000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12364000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20014000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5433000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4941000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10252000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10747000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
11962000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12494000
us-gaap Operating Expenses
OperatingExpenses
22616000
us-gaap Operating Expenses
OperatingExpenses
30761000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
101000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10865000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
58628000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
91000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2361000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11962000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12258000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22616000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30525000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
805000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
58000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1660000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
87000
CY2023Q2 us-gaap Interest Expense
InterestExpense
979000
CY2022Q2 us-gaap Interest Expense
InterestExpense
894000
us-gaap Interest Expense
InterestExpense
1981000
us-gaap Interest Expense
InterestExpense
1702000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-69000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-133000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
88000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12205000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13137000
us-gaap Net Income Loss
NetIncomeLoss
-23070000
us-gaap Net Income Loss
NetIncomeLoss
-32052000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
14000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
115000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-143000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12191000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13148000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22955000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32195000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.69
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14425775
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14425775
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6924782
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6924782
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14369643
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14369643
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6839293
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6839293
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66848000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2270000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12205000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
49407000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
59569000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2660000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18915000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
50691000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
125000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2250000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13137000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
39931000
us-gaap Net Income Loss
NetIncomeLoss
-23070000
us-gaap Net Income Loss
NetIncomeLoss
-32052000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
643000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1236000
ubx Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
653000
ubx Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
708000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
199000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
831000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-231000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
151000
us-gaap Share Based Compensation
ShareBasedCompensation
4631000
us-gaap Share Based Compensation
ShareBasedCompensation
4910000
ubx Non Cash Rent Expenses
NonCashRentExpenses
-540000
ubx Non Cash Rent Expenses
NonCashRentExpenses
-1263000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2134000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
886000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-47000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-29000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-341000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-541000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1368000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-737000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-89000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1069000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-23000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22399000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29807000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21868000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21526000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
53000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33250000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
163000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31132000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11876000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3234000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
91000
ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
125000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2351000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4468000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6382000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13463000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13632000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34351000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20014000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20888000
us-gaap Interest Paid Net
InterestPaidNet
1362000
us-gaap Interest Paid Net
InterestPaidNet
1014000
ubx Issuance Of Common Stock In Payment Of Debt
IssuanceOfCommonStockInPaymentOfDebt
0
ubx Issuance Of Common Stock In Payment Of Debt
IssuanceOfCommonStockInPaymentOfDebt
3178000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19118000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19442000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
896000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1446000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20014000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20888000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-483000000.0
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-460000000.0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12200000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13100000
us-gaap Net Income Loss
NetIncomeLoss
-23100000
us-gaap Net Income Loss
NetIncomeLoss
-32100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29800000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q2 ubx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
71000000.0
ubx Substantial Doubt About Going Concern Percentage Of Reduction In Force
SubstantialDoubtAboutGoingConcernPercentageOfReductionInForce
0.29
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:-1.764%;padding-left:1.733%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, and stock-based compensation. Actual results could differ from such estimates or assumptions.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
67741000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
136000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
67605000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
87394000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
259000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
87142000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q2 ubx Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
58000
CY2022Q4 ubx Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
378000
CY2023Q2 us-gaap Prepaid Rent
PrepaidRent
504000
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
0
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1199000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
710000
CY2023Q2 ubx Tax Credit Receivable Current
TaxCreditReceivableCurrent
1493000
CY2022Q4 ubx Tax Credit Receivable Current
TaxCreditReceivableCurrent
0
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
250000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
235000
CY2023Q2 ubx Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
370000
CY2022Q4 ubx Other Prepaid Expenses And Current Assets
OtherPrepaidExpensesAndCurrentAssets
417000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3874000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1740000
CY2023Q2 ubx Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
1500000
CY2022Q2 ubx Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
0
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
930000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1073000
us-gaap Operating Lease Cost
OperatingLeaseCost
1860000
us-gaap Operating Lease Cost
OperatingLeaseCost
2151000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
140000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
411000
us-gaap Variable Lease Cost
VariableLeaseCost
343000
us-gaap Variable Lease Cost
VariableLeaseCost
707000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
965000
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
966000
us-gaap Sublease Income
SubleaseIncome
1928000
us-gaap Sublease Income
SubleaseIncome
2014000
CY2023Q2 us-gaap Lease Cost
LeaseCost
105000
CY2022Q2 us-gaap Lease Cost
LeaseCost
518000
us-gaap Lease Cost
LeaseCost
275000
us-gaap Lease Cost
LeaseCost
844000
us-gaap Operating Lease Payments
OperatingLeasePayments
2399000
us-gaap Operating Lease Payments
OperatingLeasePayments
3416000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2411000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4964000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5123000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5287000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5457000
CY2023Q2 ubx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
11435000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
34677000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6106000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
28571000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3274000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25297000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
6825000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9941000
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
16766000
CY2023Q2 ubx Term Fee Due At Maturity Amount
TermFeeDueAtMaturityAmount
1563000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18329000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
543000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
17786000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
13704000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4082000
CY2023Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14595477
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14595477
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14215302
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14215302
CY2022Q1 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
125000000.0
CY2022Q4 ubx Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
250000000.0
CY2023Q2 ubx Restructuring And Related Activities Initiation
RestructuringAndRelatedActivitiesInitiation
2023-05-04
CY2023Q2 ubx Restructuring And Related Cost Expected Number Of Employees Eliminated
RestructuringAndRelatedCostExpectedNumberOfEmployeesEliminated
9
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.29
CY2023Q2 ubx Restructuring And Related Cost Expected Number Of Employees Eliminated
RestructuringAndRelatedCostExpectedNumberOfEmployeesEliminated
3
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1609938
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
421000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
24394
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.63
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2006544
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.90
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2361000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2250000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4631000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4910000
CY2023Q2 us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2023-05-04
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12205000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13137000
us-gaap Net Income Loss
NetIncomeLoss
-23070000
us-gaap Net Income Loss
NetIncomeLoss
-32052000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14425775
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14425775
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6924782
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6924782
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14369643
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14369643
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6839293
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6839293
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8549186
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1135397

Files In Submission

Name View Source Status
0000950170-23-039784-index-headers.html Edgar Link pending
0000950170-23-039784-index.html Edgar Link pending
0000950170-23-039784.txt Edgar Link pending
0000950170-23-039784-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ubx-20230630.htm Edgar Link pending
ubx-20230630.xsd Edgar Link pending
ubx-ex31_1.htm Edgar Link pending
ubx-ex31_2.htm Edgar Link pending
ubx-ex32_1.htm Edgar Link pending
ubx-20230630_def.xml Edgar Link unprocessable
ubx-20230630_lab.xml Edgar Link unprocessable
ubx-20230630_pre.xml Edgar Link unprocessable
ubx-20230630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
ubx-20230630_cal.xml Edgar Link unprocessable